BRPI0418845A - uso de compostos de kauranes na fabricação de medicamentos - Google Patents

uso de compostos de kauranes na fabricação de medicamentos

Info

Publication number
BRPI0418845A
BRPI0418845A BRPI0418845-4A BRPI0418845A BRPI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A
Authority
BR
Brazil
Prior art keywords
hydroxyl
compounds
methyl
ester
manufacture
Prior art date
Application number
BRPI0418845-4A
Other languages
English (en)
Inventor
We Tan
Original Assignee
We Tan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by We Tan filed Critical We Tan
Publication of BRPI0418845A publication Critical patent/BRPI0418845A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USO DE COMPOSTOS DE KAURANES NA FABRICAçãO DE MEDICAMENTOS. A invenção refere-se ao uso farmacêutico de compostos de kaurene da fórmula (I) no tratamento e prevenção de doença coronária, acidente vascular cerebral, arritmia e isquemia cerebral etc. Os referidos compostos também têm efeitos protetores significantes contra infarto isquêmico cerebral, em que R¬ 1¬: hidrogênio, hidroxila ou alcóxi, R¬ 2¬: carboxila, carboxilato, haletos de acila, aldeído, metilidroxila, e grupo de éster, acilamida, acila ou éter hidrolisável por carboxila, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 8¬: independentemente, oxigênio, hidroxila, meti-lidroxila, e éster ou grupo de alquiloximetila hidrolisável por metilldroxila, R¬ 7¬: metila, hidroxila e éster ou alquiloximetila hidrolisável por metilidroxila, R¬ 9¬: metileno ou oxigênio.
BRPI0418845-4A 2004-05-19 2004-05-19 uso de compostos de kauranes na fabricação de medicamentos BRPI0418845A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000508 WO2005110383A1 (fr) 2004-05-19 2004-05-19 Utilisation de composes de kaurane dans l'elaboration d'un medicament

Publications (1)

Publication Number Publication Date
BRPI0418845A true BRPI0418845A (pt) 2007-11-13

Family

ID=35393975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418845-4A BRPI0418845A (pt) 2004-05-19 2004-05-19 uso de compostos de kauranes na fabricação de medicamentos

Country Status (9)

Country Link
US (1) US9125877B2 (pt)
EP (1) EP1757282B1 (pt)
JP (1) JP2007538016A (pt)
CN (1) CN100508962C (pt)
AU (1) AU2004319792A1 (pt)
BR (1) BRPI0418845A (pt)
CA (1) CA2606472A1 (pt)
MX (1) MXPA06013503A (pt)
WO (1) WO2005110383A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101633609B (zh) * 2009-08-12 2013-11-06 曹庸 一种从山莓叶中分离出的新化合物、制备方法及用途
CN104529811A (zh) * 2013-11-18 2015-04-22 福建医科大学 对映贝壳杉衍生物及其制备方法和应用
CN107073022B (zh) * 2014-10-31 2020-12-29 弗雷森纽斯医疗护理德国有限责任公司 包含甜菊苷的药物组合物
WO2016077581A1 (en) * 2014-11-12 2016-05-19 University Of Florida Research Foundation, Inc. Isosteviol triazoles and uses thereof
CN112716929B (zh) * 2015-09-10 2023-03-31 东莞市凯法生物医药有限公司 贝壳杉烷类化合物在治疗心室增大及重构的药物应用
CN109925302A (zh) * 2019-02-18 2019-06-25 东莞市凯法生物医药有限公司 一种使用贝壳杉烷类化合物保护蒽环类抗肿瘤药物心脏毒性的应用
AU2020276233A1 (en) * 2019-05-13 2022-02-10 Key Pharma Biomedical Inc. New kaurane analogues,their preparation and therapeutically uses
CN115137718A (zh) * 2020-11-15 2022-10-04 珠海沅芷健康科技有限公司 一种制备恢复心脏肥厚病中减低的CNPase活性的药物的方法
CN113845424B (zh) * 2021-10-14 2023-09-12 南京医科大学 右崁醇酯类化合物及其药物用途
CN114917237A (zh) * 2022-05-13 2022-08-19 葛鹏飞 莱苞迪甙a在制备预防和/或治疗脑缺血所致神经元损伤药物中的应用
CN119015328A (zh) * 2023-05-23 2024-11-26 北京大学 贝壳杉提取物在制备抗脓毒症急性肺损伤的产品中的应用
CN118388348B (zh) * 2024-06-20 2024-12-27 广东工业大学 一种甜菊醇衍生物及其制备方法和应用
CN120518497B (zh) * 2025-07-23 2025-10-14 广东工业大学 一种c-19位修饰的异甜菊醇衍生物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002037716A (ja) * 2000-07-24 2002-02-06 Shiseido Co Ltd カウレン類含有組成物、養毛剤及び皮膚外用剤
KR100383149B1 (ko) * 2000-12-12 2003-05-12 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도
EP1361870A2 (en) * 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Also Published As

Publication number Publication date
WO2005110383A1 (fr) 2005-11-24
CN100508962C (zh) 2009-07-08
EP1757282B1 (en) 2015-02-25
EP1757282A4 (en) 2010-02-10
EP1757282A1 (en) 2007-02-28
CA2606472A1 (en) 2005-11-24
US20100179097A1 (en) 2010-07-15
AU2004319792A1 (en) 2005-11-24
JP2007538016A (ja) 2007-12-27
US9125877B2 (en) 2015-09-08
MXPA06013503A (es) 2007-06-12
CN1997358A (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
BRPI0418845A (pt) uso de compostos de kauranes na fabricação de medicamentos
BR0116607A (pt) Derivados de glicopiranosiloxipirazol e uso dos mesmos em medicamentos
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
BR0008292A (pt) Derivados de mevinolina
WO2009064023A8 (en) Skin moisturizer, blood circulation promoter, and external preparations for the skin containing the skin moisturizer and the blood circulation promoter
EP2050442A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BONE DISORDERS, FUNCTIONAL FOOD OR HEALTH MEASURES CONTAINING THIS COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AS AN ACTIVE SUBSTANCE
EP1545479A4 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
ATE418540T1 (de) Galloylpeptide
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
Belmessieri et al. Dodecyl sorbitan ethers as antimicrobials against Gram-positive bacteria
BR0013723A (pt) Uso de bissulfonamidas, para produção de medicamentos para profilaxia ou tratamento de hiperlipidemia
WO2008043974A3 (fr) Produits de soin cutané à double compartiment comprenant de l' ivermectine, et leurs utilisations

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]